Senicapoc: a potent candidate for the treatment of a subset of hereditary xerocytosis caused by mutations in the Gardos channel

Raphael Rapetti-Mauss,[1] Olivier Soriani,[1] Henri Vinti,[2] Catherine Badens,[3] and Hélène Guizouarn[1]

[1]Université Côte d'Azur, CNRS, Inserm, iBV, Nice; [2]Service d'Hématologie, Hôpital L'Archet, Nice; [3]UMR_S Inserm 910, Aix-Marseille Université, APHM Département de Génétique Médicale, Hôpital de la Timone, Centre de Référence Thalassémie, Marseille, France

Correspondence: guizouar@unice.fr
doi:10.3324/haematol.2016.149104

Supplemental figure 1



Current voltage curves recorded in a HEK cell expressing V282E KCNN4 mutant showing the effect of different doses of Senicapoc on current intensity.

Supplemental figure 2



Current voltage curves recorded in HEK cells expressing WT KCNN4 (upper graphs) or R352H mutated KCNN4 (lower graphs) showing the inhibitory effect of different doses of Senicapoc.